More importantly, M2BPGi outperforms alpha-fetoprotein (AFP) in predicting the progression to HCC in HBV patients, highlighting M2BPGi as a promising biomarker of liver fibrosis and HCC, especially in patients with chronic HBV and HCV infections (Jun et al., 2019). This evidence concerns the gene AFP and hepatocellular carcinoma.